[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Duk-Woo Park, MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":165},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,73,108,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100490954","phase-4-enavogliflozin-outcome-trial-in-patients-with-severe-aortic-stenosis-after-transcatheter-aortic-valve-replacement-100490954",false,"NCT05672836","ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement","A Randomized, Double-Blind, Placebo-controlled Trial to Evaluate Efficacy and Safety of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, Enavogliflozin Compared to Placebo on Reducing Major Cardiovascular Events or Worsening Heart Failure in Patients With Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement (TAVR) and With Heart Failure With Preserved Ejection Fraction (HFpEF)","ENAVO-TAVR","Inclusion Criteria:\n\n1\\. Patients aged ≥19 with symptomatic aortic stenosis who underwent successful transcatheter aortic valve replacement (TAVR)\\* (either native valve or valve in valve with any approved\u002Fmarketed device).\n\n\\* A successful TAVI is defined as device success according to the VARC-2(Valve Academic Research Consortium 2) and VARC-3 criteria:\n\n1. correct positioning of a single prosthetic heart valve into the proper anatomical location AND\n2. intended performance of the prosthetic heart valve (mean aortic valve gradient \\\u003C20 mmHg, peak velocity \\\u003C3 m\u002Fs, no moderate or severe prosthetic valve regurgitation) AND\n3. absence of periprocedural complications (any type of stroke, life-threatening bleeding, acute coronary artery obstruction requiring intervention, major vascular complication requiring intervention, unresolved acute valve thrombosis, or any requirement of a repeat procedure).\n\n2\\. Heart Failure with Mildly Reduced or Preserved Ejection Fraction\n\n1. Left ventricular ejection fraction (LVEF) ≥40%\n2. structural heart disease\\_Left ventricular hypertrophy (LVH) or Left atrial enlargement\n\n   A. Left ventricular hypertrophy (LVH) with septal thickness or posterior wall thickness ≥ 1.1 cm or\n\n   B. Left atrial (LA) enlargement with at least one of the following: LA width (diameter) ≥3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20cm2, or LA volume ≥ 55mL or LA volume index ≥ 29mL\u002Fm.\n3. NT-proBNP ≥ 300 pg\u002FmL (for patients without ongoing atrial fibrillation) or NT-proBNP must be ≥ 600 pg\u002FmL (for patients with ongoing atrial fibrillation).\n\n3\\. Patients who voluntarily participated in the written agreement\n\nExclusion Criteria:\n\n1. Acute decompensated Heart Failure (exacerbation of chronic Heart Failure) requiring intravenous diuretics, vasodilators, inotropic agents, or mechanical support, or hemodynamic instability following the transcatheter aortic valve replacement procedure.\n2. Currently receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomization; discontinuation of current use of SGLT2 inhibitor for the purposes of study enrolment is not permitted.\n3. Known allergy, hypersensitivity, or previous intolerance to an SGLT2 inhibitors.\n4. HF with reduced ejection fraction (LVEF \\\u003C40%).\n5. Type 1 diabetes mellitus or diabetes ketoacidosis.\n6. Chronic cystitis and\u002For recurrent urinary tract infection (≥2 times within 1 year).\n7. Stroke or transient ischemic attack within 12 weeks prior to enrollment.\n8. Symptomatic persistent hypotension and\u002For a systolic blood pressure (SBP) \\\u003C 95 mm Hg at screening or at randomization.\n9. SBP ≥180 mmHg irrespective of treatment or SBP ≥160 mmHg with at least ≥3 antihypertensive drugs at screening or randomization.\n10. Heart failure due to any of the following causes; known infiltrative cardiomyopathy (e.g. amyloid, sarcoid, lymphoma, endomyocardial fibrosis, haemochromatosis, Fabry disease), active myocarditis, constrictive pericarditis, cardiac tamponade, known hypertrophic obstructive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy\u002Fdysplasia (ARVD), or uncorrected primary valvular disease.\n11. Severe renal insufficiency (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m2 of body-surface area based on the Modification of Diet in Renal Disease (MDRD) formula) or end-stage renal disease or requiring dialysis at the time of screening.\n12. Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, esophageal varices, coagulopathy) or serum levels of transminases or alkaline phosphatase more than two times the upper limit of normal at screening.\n13. Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalization for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension.\n14. Current or suspicious malignancy or history of malignancy within 5 years\n15. Uncontrolled anaemia or haemoglobin \\\u003C9g\u002Fdl\n16. Uncontrolled hypothyroidism or arrhythmia or tachycardia\n17. Current ongoing alcoholic or drug addict\n18. Subjects with non-cardiac co-morbidities with life expectancy less than 12 months\n19. Planned major high-risk operation after transcatheter aortic valve replacement (TAVR)\n20. Women of childbearing age who have not reached a consensus on the use of highly effective contraception. Pregnancy or breastfeeding.\n21. Participation in other clinical trials, However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n    * Participating in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial.\n    * Screening failed before any interventional factor is involved.\n    * Participants who have completed their involvement in clinical trials and have surpassed a 4-week period since their last administration of the investigational drug.\n    * Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies.","ALL","19 Years",{"count":20,"type":21},1040,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this trial is to to determine whether use of a novel SGLT2 inhibitor, Enavogliflozin 0.3 mg once daily is superior to placebo, when added to standard-of-care, in reducing the composite of major cardiovascular events and Heart Failure events (hospitalization for Heart Failure or urgent Heart Failure visit) among patients who underwent transcatheter aortic valve replacement for severe aortic stenosis and with heart failure with preserved ejection fraction.",[27,28],"Aortic Valve Stenosis","Heart Failure",[30,31,32,33],"Transcatheter Aortic Valve Implantation","heart failure with preserved ejection fraction","Sodium-glucose cotransporter-2 inhibitor","transcatheter aortic valve replacement","RECRUITING","2026-06-26",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":38},"2024-12-18",{"date":42,"type":21},"2029-04",{"name":44,"class":45},"Duk-Woo Park, MD","OTHER",31,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100396548","evaluation-of-effectiveness-and-safety-of-ultimaster-tansei-stent-andor-ultimaster-nagomi-stent-in-routine-clinical-practice-100396548","NCT04443530","Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and\u002For Ultimaster Nagomi™ Stent in Routine Clinical Practice","Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and\u002For Ultimaster Nagomi™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS Tansei","Inclusion Criteria:\n\n1. Patients ≥ 19 years old\n2. Patients receiving Ultimaster™ Tansei™ stent and\u002For Ultimaster Nagomi™ stents.\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Patients with a mixture of other drug-eluting stents (DESs)\n2. Terminal illness with life-expectancy ≤1 year.\n3. Patients with cardiogenic shock",{"count":56,"type":21},2000,"OBSERVATIONAL","This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent and\u002For Ultimaster Nagomi stent in the \"real-world\" daily practice.",[60],"Coronary Artery Disease",[62,63,64],"Tansei","Ultimaster","Ultimaster Tansei","2026-06-24",{"date":35,"type":38},{"date":68,"type":38},"2020-09-17",{"date":70,"type":21},"2032-12-31",{"name":44,"class":45},11,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100394478","phase-4-potassium-competitive-acid-blocker-versus-proton-pump-inhibitor-for-gastroprotection-strategies-in-patients-at-high-gastro-intestinal-bleeding-risk-receiving-antithrombotic-therapy-100394478","NCT04416581","Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy","A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease","PROTECT-HBR","Inclusion Criteria:\n\n1. Patients 19 years of age or older with known cardiac and vascular disease who are receiving chronic use of antithrombotic drugs (either antiplatelets, oral anticoagulant (OAC), and its combinations). Specific clinical conditions that may confer a need for long-term antithrombotic therapy may include documented coronary artery disease (stable or unstable angina, acute coronary syndrome, a history of myocardial infarction, or any coronary revascularization), documented cerebrovascular disease (stroke or transient ischemic attack), known peripheral arterial disease or a history of peripheral arterial revascularization, atrial fibrillation, or valvular heart disease requiring interventions (transcatheter aortic valve replacement or transcatheter mitral-valve repair). Concomitant use of a proton pump inhibitor is strongly recommended in patients receiving aspirin monotherapy, DAPT (dual antiplatelet therapy; aspirin plus any P2Y12 inhibitors), DAT (dual antithrombotic therapy; antiplatelet drug plus OAC), TAT (triple antithrombotic therapy; DAPT plus OAC), or OAC monotherapy (warfarin or direct oral anticoagulants) who are at high risk of GI bleeding in order to reduce the risk of gastric bleed or GI events. Based on clinical guidelines, the use of P2Y12 inhibitor monotherapy (i.e. clopidogrel, ticagrelor, or prasugrel) is not considered in trial enrollment.\n2. On the basis of clinical guidelines and expert consensus documents, we defined a study population with an increased risk of gastrointestinal bleeding if they had a least 1 or more criteria of the following characteristics. Eligible patients for randomization must meet at least 1 characteristic of these criteria:\n\n   \\*Definition of patients who are at high risk of gastrointestinal bleeding\n   1. Age ≥65 years\n   2. Concomitant use of OAC and any antiplatelet therapy (mono or DAPT) (i.e., DAT or TAT)\n   3. Long-term use of oral NSAIDs (non-steroidal anti-inflammatory drugs) or steroids or high-dose NSAID therapy even during a relatively short-term period.\n   4. History of prior GI bleeding events at any time\n   5. History of a previously complicated ulcer\n   6. History of peptic ulcer disease or a previously uncomplicated ulcer\n   7. Documented Helicobacter pylori infection\n3. Patients who voluntarily participated in the written agreement\n\nExclusion Criteria:\n\n1. Active bleeding at the time of inclusion or a history of hereditary or acquired hemostatic disorder\n2. Any clinical contraindication to using of antithrombotic therapies (antiplatelet agents or OAC)\n3. Concurrent use of PPI or P-CAB within 4 weeks before randomization\n4. Hemodynamically unstable conditions at the time of inclusion: cardiogenic shock at the time of randomization, refractory ventricular arrhythmias, or congestive heart failure (New York Heart Association class IV).\n5. Baseline severe anemia (Hgb \\\u003C8 g\u002Fdl at baseline) or transfusion within 4 weeks before randomization\n6. Baseline severe thrombocytopenia (platelet count \\\u003C50,000\u002Fmm3)\n7. Renal failure dependent on dialysis or severe renal insufficiency (creatinine clearance \\\u003C15 ml\u002Fmin)\n8. Severe chronic liver disease (defined as variceal haemorrhage, ascites, hepatic encephalopathy, or jaundice)\n9. Hypersensitivity or contraindication to PPI, P-CAB, any of the product components, or substituted benzimidazoles\n10. Use of clarithromycin and hypersensitivity to macrolide antibiotics for Helicobacter pylori eradication\n11. Concomitant use of clarithromycin with terfenadine, cisapride, astemizole, or pimozide for Helicobacter pylori eradication\n12. Systemic treatment with strong CYP 3A4 and p-glycoprotein (P-GP) inhibitors (e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus \\[HIV\\]-protease inhibitors, such as ritonavir)\n13. Patients who take atazanavir, nelfinavir, or rilpivirine-containing products (see Drug-Drug interaction section)\n14. Clinically significant laboratory abnormality at screening (estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin or elevated liver enzyme \\[AST, ALT, ALP, total bilirubin\\] \\> 3 times upper normal limit \\[UNL\\] or any other condition that, in the opinion of the Investigator, precludes participation in the study\n15. Any known or suspected malignancy\n16. Patients with non-cardiac co-morbidities with a life expectancy of less than 12 months\n17. Patients with active treatment for H-pylori infection\n18. Women who are pregnant or breastfeeding or female subjects, premenopausal who are not surgically sterile, or, if sexually active not practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, who have a positive pregnancy test at screening\n19. Participation in another clinical study within 12 months. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n    1. Participated in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial\n    2. Screening failed before any interventional factor is involved\n    3. Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies",{"count":82,"type":21},3320,[24],"The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known cardiac and vascular disease receiving chronic use of antithrombotic drugs (either antiplatelets, OAC, and its combinations) who are at high GI bleeding risk. The primary hypothesis is that P-CAB (experimental arm) would non-inferior to PPI (standard arm) with respect to the rate of the primary composite end point of GI events at 12 months after randomization.",[60,86,87,88],"Percutaneous Coronary Intervention","Acute Coronary Syndrome","Myocardial Infarction",[90,91,92,93,94,95,96,97,98,99,100],"gastroduodenal ulcer","gastrointestinal hemorrhage","peptic ulcer","acute coronary syndrome","coronary artery stent placement","antiplatelet","anticoagulant therapy","PPI","P-CAB","Proton-pump inhibitors","Potassium-Competitive Acid Blockers",{"date":35,"type":38},{"date":103,"type":38},"2021-05-12",{"date":105,"type":21},"2028-02-28",{"name":44,"class":45},45,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100503117","diabetes-centered-evaluation-of-revascularization-strategy-of-functional-and-imaging-combined-state-of-the-art-percutaneous-coronary-intervention-or-coronary-artery-bypass-grafting-in-patients-with-diabetes-mellitus-and-multivessel-coronary-artery-disease-100503117","NCT05831085","Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease","A Comparison of Imaging- and Physiology-Guided State-of-the-Art Percutaneous Coronary Intervention and Coronary-Artery Bypass Grafting in Patients With Diabetes and Three-Vessel Coronary Artery Disease: DEFINE-DM Trial (Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease)","DEFINE-DM","Inclusion Criteria:\n\n1. The subject must be ≥20 years of age with angina and\u002For evidence of myocardial ischemia.\n2. Patients with type 2 diabetes based on the need for treatment with insulin or oral hypoglycemic drugs or a confirmed elevated blood glucose level (fasting plasma glucose elevation on \\>1 occasion of ≥126 mg\u002FdL \\[7.0 mmol\u002FL\\] or 2-h postprandial of ≥200 mg\u002FdL \\[11.1 mmol\u002FL\\] during oral glucose tolerance test or random plasma glucose of ≥200 mg\u002FdL \\[11.1 mmol\u002FL\\] with classic symptoms of hyperglycemia or hyperglycemic crisis or HbA1C ≥6.5% \\[48 mmol\u002Fmol\\]).\n3. Significant three-vessel CAD (defined as ≥ 50% diameter stenosis \\[DS\\] by visual estimation in each of the three major epicardial vessels or major side branches but not involving the left main coronary artery) and equivalently amenable to revascularization by means of either PCI or CABG as determined by the Heart Team at the trial site.\n4. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Unprotected left main coronary artery disease.\n2. The presence of complex coronary disease anatomy or lesion characteristics or other cardiac condition(s) which leads the participating interventional cardiologist to believe that PCI is not suitable (i.e. the subject should be managed with CABG or medical therapy alone).\n3. Recent ST-elevation myocardial infarction(\\\u003C5 days prior to randomization).\n4. Cardiogenic shock and\u002For need for mechanical\u002Fpharmacologic hemodynamic support.\n5. Severe left ventricular dysfunction (ejection fraction \\\u003C30%).\n6. Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve replacement, aorta surgery, or carotid revascularization). However, a maze procedure or pulmonary vein isolation is allowed.\n7. Contraindication or inability to take aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, or prasugrel) for at least 6 months.\n8. Prior CABG.\n9. Extremely calcified or tortuous vessels precluding FFR measurement or intracoronary imaging evaluation.\n10. More than one major epicardial vessel which is chronically occluded; enrollment of 1 Chronic total occlusion lesion is allowed.\n11. Subjects requiring or who may require additional surgery (cardiac or noncardiac) within 1 year.\n12. End-stage renal disease requiring renal replacement therapy.\n13. Liver cirrhosis.\n14. Pregnant and\u002For lactating women.\n15. Concurrent medical condition with a limited life expectancy of less than 2 years.\n16. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n1\\) Participated in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial.\n\n2\\) Screening failed before any interventional factor is involved.\n\n3\\) Participated in academic trials like strategic comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies.","20 Years",{"count":118,"type":21},1500,[120],"NA","The objective of this randomized study was to compare outcomes of imaging-and physiology-guided state-of-the-art percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG) in patients with diabetes and three-vessel CAD (not involving left main).",[123],"Coronary Artery Stenosis",[125,126,127,128,129],"Multivessel Coronary Artery Disease","state of the art","State-of-the-Art Percutaneous Coronary Intervention","Coronary-Artery Bypass Grafting","Diabetes Mellitus","2026-06-23",{"date":65,"type":38},{"date":133,"type":38},"2024-06-14",{"date":135,"type":21},"2029-12-31",{"name":44,"class":45},39,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100349165","transpacific-tavr-registry-100349165","NCT03826264","Transpacific TAVR Registry","a Multinational Multicenter Prospective Transpacific TAVR Registry","TP-TAVR","Inclusion Criteria:\n\n* All patients undergoing TAVR\n* Informed consent",{"count":147,"type":21},10000,"This registry evaluates the long-term outcome of Transcatheter aortic valve replacement (TAVR) in real-world clinical practice.",[150,151],"Heart Valve Diseases","Aortic Valve Insufficiency",[153,154,155],"TAVR","TAVI","real-world","2025-12-28",{"date":158,"type":38},"2026-01-02",{"date":160,"type":38},"2019-06-15",{"date":162,"type":21},"2036-12-31",{"name":44,"class":45},7,""]